CY1121501T1 - Συνδυαστικη θεραπεια με ενα μιτωτικο αναστολεα - Google Patents
Συνδυαστικη θεραπεια με ενα μιτωτικο αναστολεαInfo
- Publication number
- CY1121501T1 CY1121501T1 CY20191100362T CY191100362T CY1121501T1 CY 1121501 T1 CY1121501 T1 CY 1121501T1 CY 20191100362 T CY20191100362 T CY 20191100362T CY 191100362 T CY191100362 T CY 191100362T CY 1121501 T1 CY1121501 T1 CY 1121501T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inhibitors
- anticancer
- alkylating agents
- mital
- suspender
- Prior art date
Links
- 238000011284 combination treatment Methods 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 abstract 4
- 229940100198 alkylating agent Drugs 0.000 abstract 3
- 239000002168 alkylating agent Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 241000219198 Brassica Species 0.000 abstract 1
- 235000003351 Brassica cretica Nutrition 0.000 abstract 1
- 235000003343 Brassica rupestris Nutrition 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 230000000394 mitotic effect Effects 0.000 abstract 1
- 235000010460 mustard Nutrition 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Η παρούσα εφεύρεση αναφέρεται στο συνδυασμό του ΡΜ01183 με αρκετά αντικαρκινικά φάρμακα, ειδικότερα με άλλα αντικαρκινικά φάρμακα, τα οποία επιλέγονται από τα αντικαρκινικά σύμπλοκα λευκόχρυσου, τους αντιμεταβολίτες, τους μιτωτικούς αναστολείς, τα αντικαρκινικά αντιβιοτικά, τους αναστολείς τοποϊσομεράσης I ή/και II, τους αναστολείς πρωτεασώματος, τους αναστολείς δεακετυλάσης ιστόνης, τους αλκυλιωτικούς παράγοντες μουστάρδας αζώτου, τους αλκυλιωτικούς παράγοντες νιτροουρίας, τους μη κλασσικούς αλκυλιωτικούς παράγοντες, τους ανταγωνιστές οιστρογόνων, τους ανταγωνιστές ανδρογόνων, τους αναστολείς mTOR, τους αναστολείς τυροσίνης κινάσης και άλλους παράγοντες που επιλέγονται από την απλιδίνη, τα ΕΤ-743, ΡΜ02734 και ΡΜ001 04 και στη χρήση αυτών των συνδυασμών για τη θεραπεία του καρκίνου.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382300 | 2010-11-12 | ||
EP11781807.0A EP2637663B1 (en) | 2010-11-12 | 2011-11-11 | Combination therapy with an antitumor alkaloid |
PCT/EP2011/069976 WO2012062920A1 (en) | 2010-11-12 | 2011-11-11 | Combination therapy with an antitumor alkaloid |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121501T1 true CY1121501T1 (el) | 2020-05-29 |
Family
ID=44936282
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100333T CY1117466T1 (el) | 2010-11-12 | 2016-04-22 | Συνδυαστικη θεραπεια με ενα αντικαρκινικο αλκαλοειδες |
CY20191100361T CY1121504T1 (el) | 2010-11-12 | 2019-03-29 | Συνδυαστικη θεραπεια με ενα αντικαρκινικο αντιβιοτικο |
CY20191100362T CY1121501T1 (el) | 2010-11-12 | 2019-03-29 | Συνδυαστικη θεραπεια με ενα μιτωτικο αναστολεα |
CY20201100423T CY1122904T1 (el) | 2010-11-12 | 2020-05-08 | Συνδυαστικη θεραπεια με εναν αναστολεα τοποϊσομερασης |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100333T CY1117466T1 (el) | 2010-11-12 | 2016-04-22 | Συνδυαστικη θεραπεια με ενα αντικαρκινικο αλκαλοειδες |
CY20191100361T CY1121504T1 (el) | 2010-11-12 | 2019-03-29 | Συνδυαστικη θεραπεια με ενα αντικαρκινικο αντιβιοτικο |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100423T CY1122904T1 (el) | 2010-11-12 | 2020-05-08 | Συνδυαστικη θεραπεια με εναν αναστολεα τοποϊσομερασης |
Country Status (24)
Country | Link |
---|---|
US (5) | US20130266666A1 (el) |
EP (6) | EP2786755A3 (el) |
JP (4) | JP6382516B2 (el) |
KR (9) | KR102247982B1 (el) |
CN (3) | CN103282037B (el) |
AU (4) | AU2011328004C1 (el) |
BR (4) | BR122017028570B1 (el) |
CA (4) | CA2995033C (el) |
CY (4) | CY1117466T1 (el) |
DK (4) | DK2786754T3 (el) |
ES (4) | ES2790414T3 (el) |
HK (5) | HK1188572A1 (el) |
HR (4) | HRP20160361T1 (el) |
HU (4) | HUE049389T2 (el) |
LT (3) | LT2786756T (el) |
ME (3) | ME03408B (el) |
PL (4) | PL2786753T3 (el) |
PT (3) | PT2786753T (el) |
RS (4) | RS54648B1 (el) |
RU (4) | RU2605335C2 (el) |
SI (4) | SI2786753T1 (el) |
SM (1) | SMT201600112B (el) |
TR (2) | TR201904459T4 (el) |
WO (1) | WO2012062920A1 (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
BR122017028570B1 (pt) * | 2010-11-12 | 2022-03-03 | Pharma Mar, S.A | Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
KR101588949B1 (ko) * | 2014-03-13 | 2016-01-29 | 아주대학교산학협력단 | 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제 |
US11326210B2 (en) * | 2015-01-30 | 2022-05-10 | Glax Llc | Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
KR20210049403A (ko) * | 2019-10-25 | 2021-05-06 | 연세대학교 산학협력단 | 암의 예방 또는 치료용 조성물 |
MA56827B2 (fr) * | 2019-11-21 | 2023-09-27 | Pharma Mar Sa | Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine |
WO2021228414A1 (en) * | 2020-05-14 | 2021-11-18 | Pharma Mar, S.A. | Methods of treating small cell lung cancer with lurbinectedin formulations |
CN115151259A (zh) * | 2019-11-21 | 2022-10-04 | 法马马有限公司 | 用鲁比卡丁制剂治疗小细胞肺癌的方法 |
CN111298122B (zh) * | 2019-12-04 | 2021-12-21 | 哈尔滨商业大学 | 用于治疗小细胞肺癌的药物组合物及其应用 |
CN113491771A (zh) * | 2020-03-18 | 2021-10-12 | 苏州大学 | 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用 |
EP4141110A1 (en) | 2020-04-24 | 2023-03-01 | Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" | Method for producing particles of bacteriophages of the genus levivirus |
CN114470216A (zh) * | 2020-10-23 | 2022-05-13 | 和记黄埔医药(上海)有限公司 | 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法 |
CN112870194B (zh) * | 2021-01-06 | 2022-06-21 | 广州医科大学附属肿瘤医院 | 治疗肝癌的组合物及其应用 |
CN115246846A (zh) * | 2021-11-19 | 2022-10-28 | 江苏慧聚药业股份有限公司 | 卢比替定新晶型及其制备 |
WO2023165603A1 (en) * | 2022-03-03 | 2023-09-07 | Zai Lab (Shanghai) Co., Ltd. | Dna-pk inhibitor and combination use thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59225189A (ja) | 1983-06-03 | 1984-12-18 | Shionogi & Co Ltd | キノナミン誘導体およびその製造法 |
JPS6084288A (ja) | 1983-10-13 | 1985-05-13 | Shionogi & Co Ltd | シアノキノナミンアセテ−ト類およびその製造法 |
US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
AU589282B2 (en) | 1986-06-09 | 1989-10-05 | University Of Illinois | Ecteinascidins 729, 743, 745, 759a, 759b and 770 |
US5256663A (en) | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
US5721362A (en) | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
US5985876A (en) | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
IL138856A0 (en) | 1998-04-06 | 2001-10-31 | Univ Illinois | Semi-synthetic ecteinascidins |
CN100548988C (zh) | 1998-05-11 | 2009-10-14 | 法马马有限公司 | 海鞘素743的代谢物 |
US6124292A (en) | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
MY130271A (en) | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
EP1254140A4 (en) | 2000-01-19 | 2003-03-12 | Univ Columbia | SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS |
WO2001077115A1 (en) | 2000-04-12 | 2001-10-18 | Pharma Mar, S.A. | Antitumoral ecteinascidin derivatives |
MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
CA2428160C (en) * | 2000-11-06 | 2009-10-13 | Pharma Mar, S.A. | Compositions for antitumor treatment containing ecteinascidin 743 |
SE0102232L (sv) * | 2001-06-25 | 2003-02-06 | Anoto Ab | Förfarande och anordning i ett digitalt kommunikationssystem |
GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
AP2005003232A0 (en) | 2002-08-19 | 2005-03-31 | Pfizer Prod Inc | Combination therapy for hyperproliferative diseases. |
EP1572726B1 (en) | 2002-10-18 | 2010-12-08 | Pharma Mar, S.A.U. | 4-methylhexanoic kahalalide f compound |
FR2856688B1 (fr) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
US7393277B2 (en) * | 2003-08-25 | 2008-07-01 | Igt | Horseshoe payline system and games using that system |
RS50692B (sr) * | 2003-11-13 | 2010-06-30 | Pharma Mar S.A.U. | Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera |
GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
WO2005049030A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
JP2008501007A (ja) * | 2004-05-28 | 2008-01-17 | ファイザー・プロダクツ・インク | 異常な細胞増殖を治療するための方法 |
DK1658848T3 (da) | 2004-10-29 | 2007-11-26 | Pharma Mar Sa | Formuleringer omfattende ecteinascidin og et disaccharid |
AU2005316652B2 (en) | 2004-12-15 | 2009-07-23 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Combinations of therapeutic agents for treating cancer |
TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
ES2575518T3 (es) * | 2006-02-28 | 2016-06-29 | Pharma Mar S.A. | Tratamiento mejorado de mieloma múltiple |
AU2009246130A1 (en) * | 2008-05-16 | 2009-11-19 | Pharma Mar, S.A. | Combination therapy with PM00 104 and another antitumor agent |
BR122017028570B1 (pt) * | 2010-11-12 | 2022-03-03 | Pharma Mar, S.A | Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit |
-
2011
- 2011-11-11 BR BR122017028570-0A patent/BR122017028570B1/pt active IP Right Grant
- 2011-11-11 RU RU2013126630/15A patent/RU2605335C2/ru active
- 2011-11-11 PT PT14175259T patent/PT2786753T/pt unknown
- 2011-11-11 CA CA2995033A patent/CA2995033C/en active Active
- 2011-11-11 PT PT14175268T patent/PT2786754T/pt unknown
- 2011-11-11 RS RS20160181A patent/RS54648B1/en unknown
- 2011-11-11 RS RS20190380A patent/RS58608B1/sr unknown
- 2011-11-11 BR BR122017028566-1A patent/BR122017028566B1/pt active IP Right Grant
- 2011-11-11 EP EP14175275.8A patent/EP2786755A3/en not_active Withdrawn
- 2011-11-11 CA CA2817420A patent/CA2817420C/en active Active
- 2011-11-11 BR BR122017028568-8A patent/BR122017028568B1/pt active IP Right Grant
- 2011-11-11 SI SI201131699T patent/SI2786753T1/sl unknown
- 2011-11-11 DK DK14175268.3T patent/DK2786754T3/en active
- 2011-11-11 DK DK14175259.2T patent/DK2786753T3/en active
- 2011-11-11 EP EP11781807.0A patent/EP2637663B1/en active Active
- 2011-11-11 KR KR1020177031575A patent/KR102247982B1/ko active IP Right Grant
- 2011-11-11 CA CA2995025A patent/CA2995025C/en active Active
- 2011-11-11 EP EP14175268.3A patent/EP2786754B1/en active Active
- 2011-11-11 ES ES14175282T patent/ES2790414T3/es active Active
- 2011-11-11 PT PT141752824T patent/PT2786756T/pt unknown
- 2011-11-11 ME MEP-2019-91A patent/ME03408B/me unknown
- 2011-11-11 HU HUE14175282A patent/HUE049389T2/hu unknown
- 2011-11-11 RS RS20190397A patent/RS58609B1/sr unknown
- 2011-11-11 SI SI201131698T patent/SI2786754T1/sl unknown
- 2011-11-11 JP JP2013538215A patent/JP6382516B2/ja active Active
- 2011-11-11 HU HUE14175268A patent/HUE042801T2/hu unknown
- 2011-11-11 PL PL14175259T patent/PL2786753T3/pl unknown
- 2011-11-11 BR BR112013011480-0A patent/BR112013011480B1/pt active IP Right Grant
- 2011-11-11 RS RS20200506A patent/RS60236B1/sr unknown
- 2011-11-11 ES ES11781807.0T patent/ES2569180T3/es active Active
- 2011-11-11 TR TR2019/04459T patent/TR201904459T4/tr unknown
- 2011-11-11 LT LTEP14175282.4T patent/LT2786756T/lt unknown
- 2011-11-11 SI SI201130769A patent/SI2637663T1/sl unknown
- 2011-11-11 DK DK11781807.0T patent/DK2637663T3/en active
- 2011-11-11 KR KR1020177013350A patent/KR20170058454A/ko not_active Application Discontinuation
- 2011-11-11 CN CN201180063925.5A patent/CN103282037B/zh active Active
- 2011-11-11 KR KR1020197033700A patent/KR102301175B1/ko active IP Right Grant
- 2011-11-11 SI SI201131880T patent/SI2786756T1/sl unknown
- 2011-11-11 DK DK14175282.4T patent/DK2786756T3/da active
- 2011-11-11 KR KR1020217011747A patent/KR102452022B1/ko active IP Right Grant
- 2011-11-11 ES ES14175268T patent/ES2719091T3/es active Active
- 2011-11-11 CN CN201710123189.7A patent/CN106860870B/zh active Active
- 2011-11-11 HU HUE14175259A patent/HUE042802T2/hu unknown
- 2011-11-11 LT LTEP14175259.2T patent/LT2786753T/lt unknown
- 2011-11-11 PL PL14175268T patent/PL2786754T3/pl unknown
- 2011-11-11 PL PL11781807T patent/PL2637663T3/pl unknown
- 2011-11-11 TR TR2019/03859T patent/TR201903859T4/tr unknown
- 2011-11-11 WO PCT/EP2011/069976 patent/WO2012062920A1/en active Application Filing
- 2011-11-11 KR KR1020167019709A patent/KR20160088956A/ko active Search and Examination
- 2011-11-11 CA CA2995018A patent/CA2995018C/en active Active
- 2011-11-11 ES ES14175259T patent/ES2719052T3/es active Active
- 2011-11-11 KR KR1020137015020A patent/KR101716804B1/ko active IP Right Grant
- 2011-11-11 CN CN201610032547.9A patent/CN105664165A/zh active Pending
- 2011-11-11 US US13/884,874 patent/US20130266666A1/en not_active Abandoned
- 2011-11-11 ME MEP-2019-77A patent/ME03501B/me unknown
- 2011-11-11 EP EP14175282.4A patent/EP2786756B1/en active Active
- 2011-11-11 KR KR1020177022534A patent/KR20170096224A/ko active Search and Examination
- 2011-11-11 ME MEP-2016-54A patent/ME02395B/me unknown
- 2011-11-11 EP EP20155618.0A patent/EP3666275A3/en not_active Withdrawn
- 2011-11-11 LT LTEP14175268.3T patent/LT2786754T/lt unknown
- 2011-11-11 RU RU2016144668A patent/RU2743643C2/ru active
- 2011-11-11 EP EP14175259.2A patent/EP2786753B1/en active Active
- 2011-11-11 AU AU2011328004A patent/AU2011328004C1/en active Active
- 2011-11-11 PL PL14175282T patent/PL2786756T3/pl unknown
- 2011-11-11 KR KR1020177022535A patent/KR20170096065A/ko active Search and Examination
- 2011-11-11 HU HUE11781807A patent/HUE027516T2/en unknown
- 2011-11-11 KR KR1020177013349A patent/KR20170057472A/ko not_active Application Discontinuation
-
2014
- 2014-02-24 HK HK14101722.7A patent/HK1188572A1/zh unknown
- 2014-02-24 HK HK15102911.5A patent/HK1202422A1/xx unknown
- 2014-02-24 HK HK15102897.3A patent/HK1202419A1/xx unknown
- 2014-02-24 HK HK15102913.3A patent/HK1202423A1/xx unknown
- 2014-02-24 HK HK15102907.1A patent/HK1202421A1/xx unknown
-
2016
- 2016-01-13 AU AU2016200191A patent/AU2016200191B2/en active Active
- 2016-04-08 HR HRP20160361TT patent/HRP20160361T1/hr unknown
- 2016-04-19 SM SM201600112T patent/SMT201600112B/it unknown
- 2016-04-22 CY CY20161100333T patent/CY1117466T1/el unknown
- 2016-05-02 JP JP2016092369A patent/JP6723815B2/ja active Active
-
2017
- 2017-09-21 US US15/711,478 patent/US20180008602A1/en not_active Abandoned
- 2017-11-28 US US15/824,506 patent/US20180078550A1/en not_active Abandoned
- 2017-11-28 US US15/824,551 patent/US11590129B2/en active Active
- 2017-12-11 AU AU2017276157A patent/AU2017276157B2/en active Active
- 2017-12-11 AU AU2017276155A patent/AU2017276155B2/en active Active
-
2018
- 2018-01-19 RU RU2018102078A patent/RU2757373C2/ru active
- 2018-01-19 RU RU2018102080A patent/RU2767664C2/ru active
- 2018-03-27 JP JP2018059777A patent/JP6724056B2/ja active Active
- 2018-03-27 JP JP2018059776A patent/JP6724055B2/ja active Active
-
2019
- 2019-03-21 HR HRP20190554TT patent/HRP20190554T1/hr unknown
- 2019-03-22 HR HRP20190565TT patent/HRP20190565T1/hr unknown
- 2019-03-29 CY CY20191100361T patent/CY1121504T1/el unknown
- 2019-03-29 CY CY20191100362T patent/CY1121501T1/el unknown
-
2020
- 2020-04-30 HR HRP20200696TT patent/HRP20200696T1/hr unknown
- 2020-05-08 CY CY20201100423T patent/CY1122904T1/el unknown
-
2023
- 2023-01-11 US US18/095,877 patent/US20230404999A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121501T1 (el) | Συνδυαστικη θεραπεια με ενα μιτωτικο αναστολεα | |
CY1120297T1 (el) | Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων | |
CY1117340T1 (el) | Κυτταροτοξικα παραγωγα βενζοδιαζεπινης | |
CY1119324T1 (el) | Αντισωματα εναντιον csf-1r | |
CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
CY1118874T1 (el) | Ανθρωποποιημενα αντισωματα εναντια στη liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου | |
TR201810944T4 (tr) | Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri. | |
CY1119184T1 (el) | Κυκλικες ν,ν’-διαρυλοθειουριες και ν,ν’-διαρυλουριες ως ανταγωνιστες υποδοχεων ανδρογονων, αντι-καρκινικος παραγοντας, μεθοδος για παραγωγη και χρηση τους | |
CY1116703T1 (el) | ΧΡΗΣΗ sGC ΔΙΕΓΕΡΤΩΝ, sGC ΕΝΕΡΓΟΠΟΙΗΤΩΝ, MOΝΩΝ ΚΑΙ ΣΕ ΣΥΝΔΥΑΣΜΟ ME PDE5 ΑΝΑΣΤΟΛΕΙΣ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΗΣ ΣΥΣΤΗΜΙΚΗΣ ΣΚΛΗΡΥΝΣΗΣ (SSc) | |
CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
CY1118231T1 (el) | Συνθεση λιποσωματος | |
BR112015000704A2 (pt) | imidazotriazinacarbonitrilas úteis como inibidores de quinase | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
CY1119798T1 (el) | Μορφη iv υδροχλωρικης ιβαμπραδινης | |
BR112014010813A2 (pt) | n-(tetrazol-5-il)-aril-carboxamidas e n-(triazol-5-il)-aril-carboxamidas substituídas em 5-fenilo e sua utilização como herbicidas | |
CY1119999T1 (el) | Καινοτομος συνθεση για τη θεραπευτικη αντιμετωπιση της κυστικης ινωσης | |
CY1116641T1 (el) | Ενωσεις πυραζολιου ως ανταγωνιστες crth2 | |
CY1124331T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
CY1123398T1 (el) | Συνθεση συνδυασμου | |
TR201203732T1 (tr) | Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler. | |
CY1122998T1 (el) | Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη | |
CY1118585T1 (el) | Ενωση βενζοθειαζολονης | |
TR201902884T4 (tr) | Mmp akti̇f vasküler bozucu ajanlar. | |
MX2020006010A (es) | Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos. |